Small molecule inhibition of proteasome and aggresome function induces synergistic anti-tumor activity in multiple myeloma.

被引：0
|
作者：
Hideshima, T
Bradner, JE
Wong, J
Chauhan, D
Richardson, PG
Schreiber, SL
Anderson, KC
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Harvard Univ, Med Sch, Boston, MA USA
[3] Harvard Univ, Broad Inst, Cambridge, MA USA
[4] MIT, Cambridge, MA USA
[5] Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1570
引用
收藏
页码：450A / 451A
页数：2
相关论文
共 50 条
  • [21] Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
    Wen, Wei
    Han, Ernest S.
    Dellinger, Thanh H.
    Lu, Leander X.
    Wu, Jun
    Jove, Richard
    Yim, John H.
    CANCERS, 2020, 12 (09) : 1 - 17
  • [22] Ex vivo anti-tumor activity of rosiglitazone on multiple myeloma cells.
    Huang, Haiwen
    Wu, De Pei
    Leung, Anskar Y. H.
    Liang, Raymond
    Lie, Albert K. W.
    BLOOD, 2006, 108 (11) : 352B - 352B
  • [23] GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma
    Cantafio, Maria Eugenia Gallo
    Torcasio, Roberta
    Scionti, Francesca
    Mesuraca, Maria
    Ronchetti, Domenica
    Pistoni, Mariaelena
    Bellizzi, Dina
    Passarino, Giuseppe
    Morelli, Eugenio
    Neri, Antonino
    Viglietto, Giuseppe
    Amodio, Nicola
    CELLS, 2023, 12 (18)
  • [24] CD73 Dysregulates Monocyte Anti-Tumor Activity in Multiple Myeloma
    Zhou, Lin
    Liu, XiaoLan
    Guan, Tao
    Xu, HaiLing
    Wei, Fang
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 729 - 738
  • [25] NOVEL SMALL MOLECULE HPK1 INHIBITOR PCC-1 INDUCES STRONG ANTI-TUMOR ACTIVITY
    Das, Sanjib
    Mandadi, Sravan
    Saini, Jagmohan
    Chaudhari, Sachin
    Deshpande, Ameya
    Chinnapattu, Murugan
    Bajpai, Malini
    Pangre, Priyanka
    Potdar, Varada
    Marathe, Megha
    Sawant, Pooja
    Akarte, Atul
    Misra, Chandrasekhar
    Das, Subhadip
    Singh, Anuj
    Das, Avratanu
    Lambade, Pandurang
    Tirumalasetty, Chaitanya
    Patole, Raju
    Biswas, Nilanjana
    Karande, Vikas
    Shah, Heta
    Behera, Dayanidhi
    Gowda, Nagaraj
    Iyer, Pravin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A889 - A889
  • [26] Checkpoint inhibition in the treatment of multiple myeloma: A way to boost innate-like T cell anti-tumor function?
    Venken, Koen
    Favreau, Meredis
    Gaublomme, Djoere
    Menu, Eline
    Vanderkerken, Karin
    Elewaut, Dirk
    MOLECULAR IMMUNOLOGY, 2018, 101 : 521 - 526
  • [27] Pamidronate induces γδ T cell expansion in vivo and mediates anti plasma cell activity in multiple myeloma.
    Kunzmann, V
    Feurle, J
    Bauer, E
    Herderich, M
    Wilhelm, M
    BLOOD, 1998, 92 (10) : 279B - 279B
  • [28] Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
    Shen, Xuxing
    Wu, Chao
    Lei, Meng
    Yan, Qing
    Zhang, Haoyang
    Zhang, Lina
    Wang, Xueyuan
    Yang, Ye
    Li, Jianyong
    Zhu, Yongqiang
    Chen, Lijuan
    CELL DEATH & DISEASE, 2021, 12 (05)
  • [29] Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
    Xuxing Shen
    Chao Wu
    Meng Lei
    Qing Yan
    Haoyang Zhang
    Lina Zhang
    Xueyuan Wang
    Ye Yang
    Jianyong Li
    Yongqiang Zhu
    Lijuan Chen
    Cell Death & Disease, 12
  • [30] Higher doses of zoledronic acid induce in vivo anti-osteoclast as well as anti-tumor effects in patients with multiple myeloma.
    Koh, LP
    Hwang, W
    Ng, HJ
    Chuah, C
    Loh, Y
    Chow, H
    Tham, SC
    Shen, J
    Poh, CK
    Tan, P
    Teoh, G
    BLOOD, 2002, 100 (11) : 391B - 391B
12345